Publications by authors named "Oyin Opeifa"
Article Synopsis
- The study compares the cost-effectiveness of two ulcerative colitis treatments: vedolizumab and adalimumab, specifically looking at their sequences in Italy.
- A cost-effectiveness model was developed based on clinical trial data, revealing that initiating treatment with vedolizumab offers more health benefits despite being costlier than starting with adalimumab.
- The findings suggest a 94% likelihood that vedolizumab as the first treatment is economically viable at a certain cost threshold, indicating its effectiveness is retained even after switching from an anti-TNFα treatment like adalimumab.
Background/objectives: Diabetic macular oedema (DMO) is a leading cause of blindness in developed countries, with significant disease burden associated with socio-economic deprivation. Distributional cost-effectiveness analysis (DCEA) allows evaluation of health equity impacts of interventions, estimation of how health outcomes and costs are distributed in the population, and assessments of potential trade-offs between health maximisation and equity. We conducted an aggregate DCEA to determine the equity impact of faricimab.
View Article and Find Full Text PDF